Kancera develops cancer treatments of the future

Kancera unites industrial and clinical expertise. The goal is to develop a new generation of cancer drugs to combat those properties that currently cause tumors to recur, often in a more malignant and resistant form.

Kancera has four pharmaceutical projects in its existing product development portfolio, in disease areas of leukaemia and solid tumors. The development of the new drug types is being carried out as a close collaboration between clinical and industrial expertise. This creates the opportunity to make the risky development of new methods of treatment more reliable.

Kancera was founded in the spring of 2010. On February 25, 2011, the share was linked into the NASDAQ OMX First North.

Press releases


19 May
Interim Report for Kancera AB (publ) Q1 2017, January 1 – March 31, 2017
19 Jun
Bio International Convention 2017, San Diego
22 Aug
Interim Report for Kancera AB (publ) Q2 2017, January 1 – June 30, 2017


Copyright 2010 KANCERA AB, KAROLINSKA INSTITUTET SCIENCE PARK, BANVAKTSVÄGEN 22, 171 48 SOLNA. TEL: +46 (0)850 12 60 80 Website policy